Nuformix plc (LON:NFX – Get Free Report)’s stock price hit a new 52-week low on Monday . The stock traded as low as GBX 0.15 ($0.00) and last traded at GBX 0.17 ($0.00), with a volume of 3296707 shares changing hands. The stock had previously closed at GBX 0.17 ($0.00).
Nuformix Stock Performance
The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 1.12. The stock has a market cap of £1.38 million, a P/E ratio of -1.63 and a beta of 1.20. The firm has a 50 day moving average of GBX 0.18 and a two-hundred day moving average of GBX 0.20.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
Featured Articles
- Five stocks we like better than Nuformix
- How to Calculate Return on Investment (ROI)
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- What is Insider Trading? What You Can Learn from Insider Trading
- 2 Option Strategies to Maximize Profits in a Bear Market
- Why Invest in High-Yield Dividend Stocks?
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
